Publication: Real-world clinical experience of dupilumab in the treatment of chronic palmo-plantar eczema in patients with moderate-severe atopic dermatitis: 52-week follow-up
dc.contributor.author | Navarro-Triviño, Francisco José | |
dc.contributor.author | Galán-Gutiérrez, Manuel | |
dc.contributor.author | Armario-Hita, José Carlos | |
dc.contributor.author | Ruiz-Villaverde, Ricardo | |
dc.contributor.author | Domínguez-Cruz, Javier | |
dc.contributor.author | Pereyra-Rodriguez, Jose Juan | |
dc.contributor.authoraffiliation | [Navarro-Triviño,FJ; Ruiz-Villaverde,R] Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain | |
dc.contributor.authoraffiliation | [Galán-Gutiérrez,M] Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain | |
dc.contributor.authoraffiliation | [Armario-Hita,JC] Department of Dermatology, Hospital Universitario Puerto Real, Cádiz, Spain | |
dc.contributor.authoraffiliation | [Domínguez-Cruz,J; Pereyra-Rodriguez,JJ] Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain | |
dc.date.accessioned | 2025-06-12T08:57:49Z | |
dc.date.available | 2025-06-12T08:57:49Z | |
dc.date.issued | 2024-02-19 | |
dc.description.abstract | Background: Hand-foot eczema (HFE) are special locations of dermatitis, which are often associated with atopic dermatitis (AD) and have a significant negative impact on the quality of life, demanding a clinically relevant improvement. Objectives: To evaluate the effectiveness and safety of dupilumab in the treatment of eczema localized in hands and/or feet in patients with moderate-to-severe AD. Methods: Retrospective multicenter study of adult patients with HFE treated with dupilumab for their AD. Patients with other concomitantly systemic immunosuppressive treatments did not undergo a washout period. The severity of palmar and/or plantar involvement was assessed using the Physician Global Assessment (PGA) scale on a scale of 0 ( = clear) to 5 ( = very severe). Eczema Area and Severity Index (EASI) and NRS-pruritus scales were also evaluated. One hundred percent of patients reached week 16, while 67/84 reached week 52 of follow-up. Results: A total of 84 patients were included 86.69% of patients showed a reduction in PGA-Hand, and 80.34% in PGA-Foot at week 52, EASI improvement was reached by 83.55% of patients at week 16 and 87.35% at week 52. Reduction of pruritus (≥4 points in NRS-pruritus scale) was 73.01% at week 16 and 80.67% at week 52. No differences in response to dupilumab were observed in the different subtypes of palmo-plantar dermatitis. Conclusions: The results obtained in our study suggest that dupilumab may be an effective and safe therapeutic option for the treatment of dermatitis localized in hands and/or feet. | |
dc.description.version | Yes | |
dc.identifier.citation | Navarro-Triviño FJ, Galán-Gutiérrez M, Hita JC, Ruiz-Villaverde R, Domínguez-Cruz J, Pereyra-Rodríguez JJ. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis. 2024 Jan-Feb;35(S1):S55-S61 | |
dc.identifier.doi | 10.1089/derm.2023.0220 | |
dc.identifier.issn | 1710-3568 / 2162-5220) | |
dc.identifier.uri | https://hdl.handle.net/10668/28525 | |
dc.journal.title | Dermatitis | |
dc.language.iso | en | |
dc.page.number | S55-S61 | |
dc.publisher | Mary Ann Liebert, Inc Publishers | |
dc.relation.publisherversion | https://www.liebertpub.com/doi/10.1089/derm.2023.0220 | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Dupilumab | |
dc.subject | Atopic Dermatitis | |
dc.subject | Hand Eczema | |
dc.subject | Foot Eczema | |
dc.subject | Real-world Evidence | |
dc.subject.decs | Dermatitis Atópica | |
dc.subject.decs | Eccema | |
dc.subject.decs | Manos | |
dc.subject.decs | Pies | |
dc.subject.decs | Anticuerpos Monoclonales Humanizados | |
dc.subject.mesh | Dermatitis, Atopic | |
dc.subject.mesh | Eczema | |
dc.subject.mesh | Hands | |
dc.subject.mesh | Feet | |
dc.subject.mesh | Antibodies, Monoclonal, Humanized | |
dc.title | Real-world clinical experience of dupilumab in the treatment of chronic palmo-plantar eczema in patients with moderate-severe atopic dermatitis: 52-week follow-up | |
dc.type | research article | |
dc.type.hasVersion | AM | |
dc.volume.number | 35 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 47317875-9523-4829-94ac-769b6ae49c50 | |
relation.isAuthorOfPublication.latestForDiscovery | 47317875-9523-4829-94ac-769b6ae49c50 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- NavarroTrivino_Realworld.pdf
- Size:
- 696.14 KB
- Format:
- Adobe Portable Document Format